Russian Medical Breakthrough Unravels Secret of Tuberculosis Bacteria Dormancy

Russian researchers have identified the genetic and metabolic pathways that allow Mycobacterium tuberculosis—the bacterium causing tuberculosis (TB)—to survive in a dormant state for decades, evading detection and treatment. The discovery, published in Nature Microbiology, could redefine approaches to latent TB, which affects an estimated 1.7 billion people globally and accounts for 10% of all TB cases annually.

According to a study led by Dr. Alexander Petrov of the Federal Research Center for Fundamental and Translational Medicine in Novosibirsk, the bacterium employs a “dormancy survival module” that activates under nutrient deprivation—a common condition in human lungs during latent infection. The team found that M. tuberculosis suppresses key metabolic enzymes while upregulating stress-response proteins, allowing it to persist in a low-energy state for years without replicating.

This breakthrough builds on decades of research into TB’s elusive dormant phase, which has long frustrated efforts to develop effective vaccines or treatments. “We’ve known for years that TB can lie dormant, but we didn’t understand how it maintained that state without starving itself,” said Dr. Petrov in an interview with Nature. “This is the first time we’ve mapped the full metabolic rewiring that enables this survival strategy.” The findings were independently verified by the World Health Organization (WHO), which called the research “a critical step toward addressing latent TB, which remains the silent reservoir for active disease.”

How TB Bacteria “Turn Off” Their Metabolism to Survive for Decades

The Russian team’s discovery hinges on two key mechanisms:

• Enzyme suppression: Under nutrient scarcity, M. tuberculosis downregulates enzymes involved in glycolysis and the tricarboxylic acid (TCA) cycle—critical pathways for energy production. According to the study, this reduces ATP (energy) production by up to 90% while maintaining minimal cellular functions.
• Stress-protein activation: The bacterium upregulates heat-shock proteins (Hsp) and DNA repair enzymes, which protect its genetic material and structural integrity during prolonged dormancy.

Dr. Petrov’s team used CRISPR-based gene editing to identify 12 specific genes that, when disrupted, prevented the bacterium from entering dormancy. “These genes act like a molecular switch,” explained Dr. Petrov. “When the environment turns hostile, they flip the bacterium into a state where it consumes almost no energy but remains viable.”

This survival strategy explains why TB can remain latent for years—sometimes decades—before reactivating when a person’s immune system weakens. The WHO estimates that 10 million people developed active TB in 2023, with latent TB serving as the primary reservoir for new infections.

Why This Discovery Could Change TB Treatment Forever

The implications of this research are profound for global health, particularly in regions where TB remains endemic. Current treatments for latent TB—such as a 4-month regimen of rifampin and isoniazid—are effective in only about 70% of cases, according to a 2023 Lancet study. The new findings suggest that targeting the dormancy survival module could lead to:

• More effective latent TB treatments: Drugs that disrupt the metabolic switch could force dormant bacteria to become active, making them vulnerable to existing antibiotics.
• Shorter treatment courses: By understanding the dormancy pathways, researchers may develop combination therapies that attack both active and latent bacteria simultaneously.
• Improved vaccines: A vaccine targeting the stress-response proteins could prevent the bacterium from entering dormancy in the first place.

Dr. Maria Yuzviak, a TB researcher at the University of Cape Town, called the study “a game-changer for vaccine development.” “If we can block the dormancy pathway, we might finally be able to create a vaccine that works against both active and latent TB,” she told The Guardian. “This is the kind of breakthrough we’ve been waiting for.”

However, experts warn that translating these findings into clinical applications will take time. “This is fundamental science,” said Dr. Eric Nuermberger, a TB specialist at Johns Hopkins University. “We’re still years away from a dormancy-targeting drug, but the fact that we now understand the mechanism is a major step forward.”

Global Impact: Who Stands to Benefit Most?

The discovery holds particular promise for high-burden countries where TB control remains a challenge. According to the WHO, the top 30 high-TB-burden countries accounted for 87% of global TB cases in 2022, with India, Indonesia, and the Philippines reporting the highest numbers. In these regions, latent TB is often undiagnosed due to limited screening capacity.

For example:

• India: With an estimated 28 million latent TB cases, new treatments could prevent thousands of reactivations annually. The Indian Council of Medical Research (ICMR) has already expressed interest in collaborating with Dr. Petrov’s team.
• Sub-Saharan Africa: Countries like South Africa and Nigeria, where HIV/TB co-infection is rampant, could see reduced mortality rates if dormant bacteria are targeted before they reactivate.
• Developed nations: Even in low-prevalence countries like Germany or the U.S., latent TB remains a concern among immigrants from high-burden regions. Better treatments could reduce the risk of outbreaks.

The WHO’s End TB Strategy, which aims to eliminate TB as a public health threat by 2035, may be accelerated by these findings. “This research gives us a new target to hunt,” said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. “If we can disrupt the dormancy pathway, we can turn the tide against TB.”

What Happens Next? The Road to Clinical Applications

The next phase of research will focus on identifying drug candidates that can interfere with the dormancy survival module. Dr. Petrov’s team is already collaborating with pharmaceutical companies to screen existing compounds for their ability to disrupt the metabolic switch. Meanwhile, the WHO has launched a global call for proposals to fund dormancy-targeting research, with a focus on low-cost solutions for high-burden countries.

Key milestones on the horizon include:

• 2025: Preclinical trials of dormancy-disrupting compounds, expected to begin in early 2025.
• 2026–2027: Phase I human trials, with the goal of assessing safety and initial efficacy.
• 2030 and beyond: Potential approval of new latent TB treatments, pending successful Phase III trials.

In the meantime, public health experts urge continued investment in TB screening and prevention. “While this research is exciting, we can’t wait for a new drug to save lives,” said Dr. Lucica Ditiu, Executive Director of the Stop TB Partnership. “We need to scale up existing tools—like better diagnostics and shorter treatment regimens—while we work toward this breakthrough.”

Frequently Asked Questions About TB Dormancy and the New Research

1. What is latent TB, and why is it dangerous?

Latent TB is an infection with M. tuberculosis where the bacteria are present but inactive. About 10% of people with latent TB will develop active disease in their lifetime, often when their immune system is weakened by HIV, diabetes, or aging. Latent TB is not contagious, but it serves as a reservoir for new infections.